康莱特注射液配合化疗对肝癌的治疗效果及免疫细胞活性的影响

目的:观察康莱特注射液联合化疗对肝癌患者的临床疗效及其对患者自身免疫细胞活性的影响。方法:收集150例确诊为肝癌的患者,随机平均分为对照组与治疗组。其中对照组患者采用西医方案进行化疗,治疗组在对照组的基础上给予康莱特注射液配合治疗,连续治疗2个月后,观察两组患者治疗前后的近期疗效、体重变化、生活质量改善、化疗毒性反应、患者治疗1、3、5年后的生存率及对免疫细胞活性的影响。结果:对照组与治疗组近期总有效率分别为44%、68%,治疗组显著高于对照组;对照组与治疗组患者生活质量改善率分别为33.3%、66.7%,治疗组显著高于对照组;治疗前后对照组与治疗组的体质量变化好转率分别为21.3%、24%,差异不显著;对照组患者治疗1、3、5年后的生存率明显低于治疗组;治疗组患者在治疗后,免疫力明显提升,两组患者治疗后各免疫学指标相比差异显著;对照组化疗毒性反应明显高于治疗组。结论:采用康莱特注射液联合化疗可以明显提高肝癌患者的治疗效果与免疫细胞的活性,有效缓解患者的临床症状,提高生活质量,明显降低化疗药物的不良反应。

Clinical efficacy and Influence of Kanglaite Combined with Chemotherapy on the Activity of Immune Cells in Patients with Liver Cancer

Objective： To observe the clinical effects of Kanglaite applied to the chemotherapy on the activity of immune cells in patients with liver cancer. Methods： 150 patients who were diagnosed the liver cancer were collected and randomly divided into the control group and the treatment group by average. The patients in the control group were treated by chemotherapy with western medicine, while the patients in the treatment group were treated by Kanglaite combined with the chemotherapy mixed with the western medicine. After treating for two months, the recent curative effect, variation of body weight, the improvement of the life quality, the adverse reaction of patients were observed. The survival rate of one-year, three-year and five-year after the treatment was analyzed and the activity of immune cells in patients was compared before and after the treatment. Results： The rate of short-term efficacy of patients in the control group was 44% and 68% in the treatment group with statistically significant differences （P〈0.05）; The improvement of life quality of patients in the control groups was 33.3%, while in the treatment group was 66.7% with statistically significant difference（P〈0.05）; The variation of body weight in the control group was 21.3%, while in the treatment group was 24% with statistically significant difference （P〈0.05）; The rate of survival in the treatment group was higher than that of the control group when treated for one-year, three-year and five-year later; The activity of immunity of patients in the treatment group were significantly improved after treatment, and the immuno-logical indexes of patients in the two groups after treatment were significantly different; The adverse reaction of patients in the control group is significantly higher than that of the treatment group（P〈0.05）. Conclusions： It is indicated that the application of Kanglaite combined with chemotherapy should be well promoted in the clinical field with the advantages of better efficacy, and the stimulation of immune cells＇ activity for the patients with liver cancer.